Wednesday, 7 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange

Medplus Health Services Ltd

NSE: MEDPLUS · BSE: 543427 · Healthcare · 93 announcements

Share price
₹646.80
Market cap
₹7,770 Cr
Revenue (annual)
₹6,892 Cr
Net profit (annual)
₹219.7 Cr
P/E (TTM)
36.9×Sector 53.1×
Promoter holding
40.19%-0.03% QoQ
FII holding
14.38%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

19:09 IST BSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus Health Services' subsidiary, Optival Health Solutions, faced a three-day drug license suspension at a store by the Drugs Control Administration, impacting operations by ₹0.01 Crore.

Value
₹0.01 Cr
From
Drugs Control Administration, Haveri Circle, Karnataka
17:20 IST BSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus Health Services reported a 7-day drug license suspension for a subsidiary store, impacting its operations with an estimated financial loss of ₹0.02 Crore.

Value
₹0.02 Cr
Execution
7 days
13:56 IST BSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus Health Services' subsidiary, Optival Health Solutions, faced drug license suspensions for two stores from regulatory authorities, causing a total financial impact of Rs 0.0961 Crore.

Value
₹0.10 Cr
Execution
5 to 15 days
17:07 IST BSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus Health Services' subsidiary, Optival Health Solutions, faced a five-day drug license suspension at its Kapikad store due to regulatory violations. The impact is Rs 0.03 Crore.

Value
₹0.03 Cr
suspension period
5.0 days
17:21 IST BSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus Health's subsidiary faces temporary drug license suspensions at two store locations in Bangalore and Pune, resulting in an estimated financial impact of Rs 0.15 Crore.

Value
₹0.15 Cr
17:53 IST BSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

MedPlus's subsidiary faces a 7-day drug license suspension at a Maharashtra store, with an estimated financial impact of Rs 0.0175 Crore.

Value
₹0.02 Cr
Execution
7 days
17:41 IST BSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus Health Services reported 7-day drug license suspensions for four stores across three states. The estimated financial impact of these operational disruptions is ₹0.09 Crore.

Value
₹0.09 Cr
17:33 IST BSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus Health Services' subsidiary, Optival Health Solutions, faces temporary drug license suspensions for two stores. The estimated financial impact is Rs 0.03 Crore.

Value
₹0.03 Cr
18:44 IST NSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus Health Services reported a 25-day drug license suspension for its Latur store, with an estimated financial impact of Rs 0.11 Crore.

Value
₹0.11 Cr
Execution
25 days
18:38 IST NSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

MedPlus's subsidiary, Optival Health Solutions, received a two-day drug license suspension for a store in Karnataka. The potential revenue impact is Rs 0.0071 Crore.

Value
₹0.01 Cr
17:47 IST BSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus Health Services' subsidiary, Optival Health Solutions, received a two-day drug license suspension for a Karnataka store. The financial impact is estimated at ₹0.0029 Crore.

Execution
2 days
18:33 IST BSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

MedPlus Health Services' subsidiary, Optival Health, received two-day drug license suspensions for three stores. The total estimated potential revenue loss is ₹0.024 Crore.

Value
₹0.02 Cr
18:21 IST NSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

MedPlus subsidiary Optival Health Solutions faces a 2-day drug license suspension at a Karnataka store, with a potential revenue loss of ₹0.0053 Crore.

Value
₹0.01 Cr
Execution
2 days
17:54 IST NSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

MedPlus subsidiary Optival Health Solutions faced one to two-day drug license suspensions across three Karnataka stores. The estimated total revenue impact is approximately Rs. 1.59 lakhs.

Value
₹0.02 Cr
Execution
1-2 days
14:08 IST BSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus subsidiary received a 5-day drug license suspension in Maharashtra. Potential revenue loss of Rs. 0.75 lacs is quantified for investors.

Value
₹0.01 Cr
15:38 IST BSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus subsidiary received a 3-day drug license suspension in Bangalore. Potential revenue loss of Rs 5.13 lacs is quantified for investors.

Value
₹0.05 Cr
19:05 IST NSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus subsidiary faces a two-day drug license suspension for one store in Davanagere. The estimated financial impact is 0.008 Crore due to regulatory non-compliance.

Value
₹0.01 Cr
Execution
2 days
18:04 IST NSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus subsidiary Optival Health Solutions faced one-day drug license suspensions at two Karnataka stores. The regulatory action follows violations of the Drugs and Cosmetics Act.

Execution
1 Day
15:59 IST NSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

MedPlus subsidiary received two drug license suspension orders for a Karnataka store. This halts operations at the specific location.

01:10 IST NSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

MedPlus subsidiary Optival Health Solutions faced one-to-three-day license suspensions at three stores in Karnataka and Andhra Pradesh. Estimated financial impact is Rs 0.0158 Crore.

Value
₹0.02 Cr
Execution
1 to 3 days
18:17 IST BSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

MedPlus reports drug license suspensions for three stores. The incident causes a minimal potential revenue loss of ₹0.02 Crore.

Value
₹0.02 Cr
17:35 IST NSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

MedPlus subsidiary Optival Health's Karnataka store faced a one-day drug license suspension. This resulted in a potential revenue loss of ₹0.0046 Crore.

Value
₹0.46 Cr
Execution
one day
17:48 IST NSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus subsidiary stores in Andhra Pradesh faced drug license suspensions. This results in a total potential revenue loss of ₹0.03 Crore.

Value
₹2.92 Cr
16:33 IST NSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

MedPlus subsidiary received a two-day drug license suspension in Karnataka. The potential revenue loss is Rs 1.48 lacs, with limited financial impact.

17:46 IST NSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

MedPlus subsidiary Optival Health Solutions faced a 15-day drug license suspension at its Ongole store. The disruption causes an estimated ₹0.02 Crore revenue loss.

Value
₹0.02 Cr
Execution
15 days
17:48 IST NSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

MedPlus subsidiary Optival Health Solutions received drug license suspensions for two Telangana stores. The temporary closures result in a combined potential revenue loss of ₹0.01 Crore.

Value
₹0.01 Cr
18:49 IST NSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

MedPlus subsidiary Optival Health Solutions received drug license suspension orders for two Karnataka stores. The temporary closures will result in a combined ₹0.03 Crore revenue loss.

Value
₹0.03 Cr
Execution
2-3 days
17:53 IST NSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

MedPlus Health Services subsidiary received two drug license suspension orders for stores in Telangana and Karnataka. The suspensions cause a ₹0.05 Crore total potential revenue loss.

Value
₹0.05 Cr
15:14 IST NSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

MedPlus subsidiary Optival Health Solutions received a three-day drug license suspension for a Telangana store. The event carries a potential ₹0.02 Crore revenue impact.

Value
₹0.02 Cr
Execution
3 days
16:33 IST NSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

MedPlus subsidiary Optival Health Solutions received a two-day drug license suspension for its Karnataka store. The temporary closure results in a ₹0.01 Crore revenue loss.

Value
₹0.01 Cr
Execution
2 days